|
1
|
Ali S and Coombes RC: Estrogen receptor
alpha in human breast cancer: Occurrence and significance. J
Mammary Gland Biol Neoplasia. 5:271–281. 2000. View Article : Google Scholar
|
|
2
|
Hall JM, Couse JF and Korach KS: The
multifaceted mechanisms of estradiol and estrogen receptor
signaling. J Biol Chem. 276:36869–36872. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Couse JF and Korach KS: Estrogen receptor
null mice: What have we learned and where will they lead us? Endocr
Rev. 20:358–417. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colditz GA: Relationship between estrogen
levels, use of hormone replacement therapy, and breast cancer. J
Natl Cancer Inst. 90:814–823. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hankinson SE, Colditz GA and Willett WC:
Towards an integrated model for breast cancer etiology: The
lifelong interplay of genes, lifestyle, and hormones. Breast Cancer
Res. 6:213–218. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uray IP and Brown PH: Chemoprevention of
hormone receptor-negative breast cancer: New approaches needed.
Clinical Cancer Prevention. Springer; pp. 147–162. 2011
|
|
7
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res. 3:1451–1461. 2010. View Article : Google Scholar
|
|
13
|
Bosco JLF, Antonsen S, Sørensen HT,
Pedersen L and Lash TL: Metformin and incident breast cancer among
diabetic women: A population-based case-control study in Denmark.
Cancer Epidemiol Biomarkers Prev. 20:101–111. 2011. View Article : Google Scholar
|
|
14
|
Beck E and Scheen AJ: Metformin, an
antidiabetic molecule with anti-cancer properties. Rev Med Liege.
68:444–449. 2013.In French. PubMed/NCBI
|
|
15
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiralerspong S, Gonzalez-Angulo AM and
Hung M-C: Expanding the arsenal: Metformin for the treatment of
triple-negative breast cancer? Cell Cycle. 8:2681–2684. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marx J: Medicine. Cancer-suppressing
enzyme adds a link to type 2 diabetes. Science. 310:1259. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goodwin PJ, Pritchard KI, Ennis M, Clemons
M, Graham M and Fantus IG: Insulin-lowering effects of metformin in
women with early breast cancer. Clin Breast Cancer. 8:501–505.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dowling RJ, Goodwin PJ and Stambolic V:
Understanding the benefit of metformin use in cancer treatment. BMC
Med. 9:332011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Markowska A, Pawałowska M, Filas V, Korski
K, Gryboś M, Sajdak S, Olejek A, Bednarek W, Spiewankiewicz B,
Lubin J, et al: Does Metformin affect ER, PR, IGF-1R, β-catenin and
PAX-2 expression in women with diabetes mellitus and endometrial
cancer? Diabetol Metab Syndr. 5:762013. View Article : Google Scholar
|
|
21
|
Yoo YA, Kim YH, Kim JS and Seo JH: The
functional implications of Akt activity and TGF-beta signaling in
tamoxifen-resistant breast cancer. Biochim Biophys Acta.
1783:438–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dauvois S, Danielian PS, White R and
Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen
receptor content by increasing its turnover. Proc Natl Acad Sci
USA. 89:4037–4041. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clark GM, Osborne CK and McGuire WL:
Correlations between estrogen receptor, progesterone receptor, and
patient characteristics in human breast cancer. J Clin Oncol.
2:1102–1109. 1984.PubMed/NCBI
|
|
25
|
Honig SF: Tamoxifen for the reduction in
the incidence of breast cancer in women at high risk for breast
cancer. Ann NY Acad Sci. 949:345–348. 2001. View Article : Google Scholar
|
|
26
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar
|
|
27
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonzalez-Angulo AM and Meric-Bernstam F:
Metformin: A therapeutic opportunity in breast cancer. Clin Cancer
Res. 16:1695–1700. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gullick WJ, Berger MS, Bennett PL,
Rothbard JB and Waterfield MD: Expression of the c-erbB-2 protein
in normal and transformed cells. Int J Cancer. 40:246–254. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
King CR, Kraus MH and Aaronson SA:
Amplification of a novel v-erbB-related gene in a human mammary
carcinoma. Science. 229:974–976. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Riese DJ II, van Raaij TM, Plowman GD,
Andrews GC and Stern DF: The cellular response to neuregulins is
governed by complex interactions of the erbB receptor family. Mol
Cell Biol. 15:5770–5776. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ross JS and Fletcher JA: The HER-2/neu
oncogene in breast cancer: Prognostic factor, predictive factor,
and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim J, Lee J, Kim C, Choi J and Kim A:
Anti-cancer effect of metformin by suppressing signaling pathway of
HER2 and HER3 in tamoxifen-resistant breast cancer cells. Tumour
Biol. Nov 18–2015.Epub ahead of print. View Article : Google Scholar
|
